Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma Group

NCT05270044 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT05270044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05270044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma Group
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 2, 2022
Completion date
May 2, 2035
Enrollment
815 (estimated)
Sites
155

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma